NVNO enVVeno Medical Corp

Price (delayed)

$5.99

Market cap

$79.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$78.85M

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product ...

Highlights
The EPS has grown by 28% year-on-year and by 13% since the previous quarter
NVNO's debt is down by 20% YoY and by 6% from the previous quarter
The equity rose by 24% year-on-year but it has declined by 8% since the previous quarter
NVNO's quick ratio is down by 15% QoQ

Key stats

What are the main financial stats of NVNO
Market
Shares outstanding
13.33M
Market cap
$79.85M
Enterprise value
$78.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.88
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$22.12M
EBITDA
-$21.57M
Free cash flow
-$17.34M
Per share
EPS
-$1.66
Free cash flow per share
-$1.08
Book value per share
$3.18
Revenue per share
$0
TBVPS
$2.79
Balance sheet
Total assets
$44.83M
Total liabilities
$2.46M
Debt
$1.32M
Equity
$42.37M
Working capital
$41.76M
Liquidity
Debt to equity
0.03
Current ratio
29.08
Quick ratio
28.88
Net debt/EBITDA
0.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-57.6%
Return on equity
-62.2%
Return on invested capital
-64.6%
Return on capital employed
-51%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVNO stock price

How has the enVVeno Medical stock price performed over time
Intraday
0.67%
1 week
14.97%
1 month
25.05%
1 year
43.99%
YTD
16.54%
QTD
14.1%

Financial performance

How have enVVeno Medical's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.94M
Net income
-$22.12M
Gross margin
N/A
Net margin
N/A
enVVeno Medical's net income has increased by 14% YoY and by 6% from the previous quarter
enVVeno Medical's operating income has increased by 9% YoY and by 5% QoQ

Growth

What is enVVeno Medical's growth rate over time

Valuation

What is enVVeno Medical stock price valuation
P/E
N/A
P/B
1.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 28% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 46% lower than the 5-year quarterly average of 3.5 but 18% higher than the last 4 quarters average of 1.6
The equity rose by 24% year-on-year but it has declined by 8% since the previous quarter

Efficiency

How efficient is enVVeno Medical business performance
The ROIC has grown by 11% from the previous quarter and by 2.1% YoY
NVNO's ROE is up by 11% since the previous quarter and by 2% year-on-year
The company's return on assets rose by 11% QoQ and by 2.9% YoY

Dividends

What is NVNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVNO.

Financial health

How did enVVeno Medical financials performed over time
enVVeno Medical's total assets has increased by 22% YoY but it has decreased by 8% from the previous quarter
enVVeno Medical's current ratio has decreased by 15% from the previous quarter
NVNO's debt is 97% less than its equity
The company's debt to equity fell by 40% YoY
The equity rose by 24% year-on-year but it has declined by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.